<DOC>
	<DOCNO>NCT00533793</DOCNO>
	<brief_summary>A phase 2 , prospective , randomize , control , open-label ( dose-blinded ) , parallel group , international multi-center study . The study consist four treatment group - one control group ( SoC ) three I-040202 group receive SoC plus 0.133 mg/mL , 0.4 mg/mL 1.0 mg/mL I-040202 .</brief_summary>
	<brief_title>Adjunctive Therapy Treat Tibial Shaft Fractures</brief_title>
	<detailed_description />
	<criteria>Eligible patient must meet follow inclusion criterion : 1. patient acute open fracture tibial shaft secondary trauma assess medical examination current radiograph indicate open fracture reduction internal fixation use osteosynthesis plate intramedullary nail 2. soft tissue management ( medically warrant , eg . debridement , irrigation , application antibiotic ) perform accord local hospital practice later 24h trauma 3. male female patient &gt; = 18 year 4. body mass index ( BMI ) 1633 ( minimum body weight 50 kg , maximum 140 kg ) 5. female childbearing potential must willing undergo pregnancy test ( urine ) prior treatment start ( screen ) 6. female childbearing potential randomize intervention group must agree acceptable contraception least 3 month receive study medication . Acceptable contraceptive measure : Hormonal type birth control failure rate le 1 % per year ( implant , injection , combine oral contraceptive , patch method ) copper IUDs IUDs failure rate le 1 % per year , AND An additional barrier type birth control measure ( condom , diaphragm , cervical cap , etc . ) Sterilized woman abstinent woman childbearing potential require take contraceptive measure 7. willingness ability understand , participate comply study requirement 8. patient able give consent personally sign Informed Consent Form . Exclusion criterion : Patients eligible meet one follow exclusion criterion : 1 . IIIc open fracture accord GustiloAnderson classification 2. tibial defect require bonegrafting ( e.g . large segmental defect ) 3. duration trauma surgery longer 14 day 4. concomitant acute bone injury and/or major skin significant injury opinion investigator would interfere tibial shaft fracture heal process 5. concomitant ipsilateral tibial fracture diaphyseal region 6. evidence immune suppression 7. suspect know hypersensitivity study medication component 8. evidence hypercalcemia 9. hyperparathyroidism 10. treatment and/or plan treatment product contain PTH ( e.g . Forteo ) 11. pregnant lactate female 12. participation another clinical trial within last 3 month 13. active past history malignant tumor 14. history evidence hereditary acquire chronic metabolic bone disease primary osteoporosis . 15. history evidence clinically relevant organ failure relevant medical condition , opinion investigator , relevantly interfere assessment study outcome impose hazard patient study therapy initiate 16. known history allergy anaesthetic 17. evidence moderate severe renal failure ( serum creatinine &gt; 3.0 time ULN , NCI CTC grade 3 4 ) 18. know history allergic thrombocytopenia ( type II ) induce heparin 19. inexplicable elevation alkaline phosphatase alkaline phosphatase &gt; 5.0 time ULN , NCI CTC grade 3 4 20. prior external beam implant radiation therapy skeleton</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bone , tibial shaft fracture</keyword>
</DOC>